Back to search

Article

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer

2025-10-14

Abstract excerpt

<h4>Background: </h4> Circulating tumor DNA (ctDNA) analysis offers a non-invasive approach to molecular profiling. While RAS mutations are well-established predictive biomarkers in metastatic colorectal cancer (mCRC), the prognostic value of their variant allele fre-quency (VAF) remains unclear. <h4>Methods:</h4> We retrospectively analyzed individual patient data with mCRC who un-derwent ctDNA testing using the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eddf124d-4e4f-56ba-a113-f04b515f5829
DOI
10.20944/preprints202510.0997.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal CancerDOI 10.20944/preprints202510.0997.v1
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.Semantic proximity
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.Semantic proximity
Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancerSemantic proximity
Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.Semantic proximity
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.Semantic proximity
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.Semantic proximity
RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.Semantic proximity
Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity
Association of Emergence of New Mutations in Circulating Tumuor DNA During Chemotherapy With Clinical Outcome in Metastatic Colorectal CancerSemantic proximity
Select a neighboring publication to make it the new centre.